Screening for pre‐eclampsia with competing‐risks model using placental growth factor measurement in blood samples collected before 11 weeks' gestation

• Published in: Ultrasound in obstetrics & gynecology 2024-03, Vol.63 (3), p.342-349
• Main Authors: Riishede, I., Ekelund, C. K., Sperling, L., Overgaard, M., Knudsen, C. S., Clausen, T. D., Pihl, K., Zingenberg, H. J., Wright, A., Wright, D., Tabor, A., Rode, L., Andersen, M. R., Bendix, E. J., Gjerris, A. C., Hillig, T., Jakobsen, T. R., Jørgensen, F. S., Munk, J. K., Sandager, P., Wagner, S. R.
• Format: Article
• Language: English
• Subjects: Algorithms; competing‐risks model; Female; Fetal Medicine Foundation; first trimester; Gestational Age; Humans; Infant, Newborn; Placenta Growth Factor; placental growth factor; Pre-Eclampsia - diagnosis; Pregnancy; pre‐eclampsia; Prospective Studies; screening
• ISSN: 0960-7692; 1469-0705
• DOI: 10.1002/uog.27462

ABSTRACT Objectives To describe the distributional properties and assess the performance of placental growth factor (PlGF) measured in blood samples collected before 11 weeks' gestation in the prediction of pre‐eclampsia (PE). Methods The study population consisted of pregnant women included in the Pre‐eclampsia Screening in Denmark (PRESIDE) study with a PlGF measurement from the routine combined first‐trimester screening (cFTS) blood sample collected at 8–14 weeks' gestation. PRESIDE was a prospective multicenter study investigating the predictive performance of the Fetal Medicine Foundation (FMF) first‐trimester screening algorithm for PE in a Danish population. In the current study, serum concentration of PlGF in the cFTS blood samples was analyzed in batches between January and June 2021. Results A total of 8386 pregnant women were included. The incidence of PE was 0.7% at